Open · 42 days left D National Institutes of Health

Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)

Funding

Not specified

Deadline

Days

Hrs

Min

Sec

Apr 03, 2026

Posted May 19, 2023 (1007 days ago)

Closes Apr 3, 2026 (in 42 days)

Grant Details

Agency

National Institutes of Health

Opportunity Number

PAR-23-193

CFDA / ALN

93.865

Opportunity Category

Discretionary (D)

Funding Category

HL, ISS

Funding Instrument

Grant (G)

Cost Sharing

No Cost Sharing (No)

Eligibility

State governments (00) County governments (01) City or township governments (02) Special district governments (04) Independent school districts (05) Public and State controlled institutions of higher education (06) Native American tribal governments (Federally recognized) (07) Public housing authorities / Indian housing authorities (08) Native American tribal organizations (11) Nonprofits having a 501(c)(3) status with the IRS (12) Nonprofits without 501(c)(3) status (13) Private institutions of higher education (20) For-profit organizations other than small businesses (22) Small businesses (23) Others (25)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Description

The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). The long-term objective is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in the field of contraception, and/or reproductive health related indications (pending contractor availability and available funding).

Apply on Grants.gov Apply Now